nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
By D. Goldstein, R. El-Maraghi, P. Hammel, V. Heinemann, V. Kunzmann, J. Sastre, W. Scheithauer, S. Siena, J. Tabernero, Luis Teixeira and 7 more. Journal of the National Cancer Institute, 2015
625 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/e7858593447732402b881fc936681a822dbdd4cd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- W. Hawkins
- F. Balkwill
- Japanese Gastric Cancer Association
- J. Joyce
- Lisa M. Coussens
- A. Mantovani
- M. Karin
- A. Sica
Citations in the corpus
- Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, methodology): “Updated results of theMPACT trial show that long-term survival is possible with gemcitabine plus albumin-bound paclitaxel, as 3% of patients from that arm were alive at 42 months, whereas no patients were alive from the control arm at that time.(166) Factors associated with survival in this trial in”
- CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma (2016, positive): “Recent improvements in survival using FOLFIRINOX and gemcitabine plus nab-paclitaxel have offered a choice to clinicians for the first time (Conroy et al., 2011; Goldstein et al., 2015).”